Tags

Type your tag names separated by a space and hit enter

Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.

Abstract

Sativex is one of the first cannabis-based medicines to undergo conventional clinical development and to be approved as a prescription medicine. It is an oromucosal spray that allows flexible, individualised dosing. Patients self titrate their overall dose and pattern of dosing according to their response to and tolerance of the medicine. This usually results in the administration of approximately 8-12 sprays/day. Each spray delivers tetrahydrocannabinol 2.7 mg and cannabidiol 2.5 mg, giving an approximate average dose of tetrahydrocannabinol 22-32 mg/day and cannabidiol 20-30 mg/day. Development has concentrated on the treatment of symptoms of multiple sclerosis, notably spasticity and neuropathic pain, as well as the treatment of neuropathic pain of other aetiologies. Positive results in placebo-controlled trials of the use of Sativex as an add-on therapy in these indications demonstrate that Sativex is efficacious and well tolerated in the treatment of these symptoms. Sativex has been approved for use in neuropathic pain due to multiple sclerosis in Canada. If ongoing studies replicate the results already observed, further approvals for the treatment of spasticity in multiple sclerosis and for neuropathic pain are likely.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    Hunters Moor Regional Neurological Rehabilitation Centre, Newcastle upon Tyne, NE2 4NR, UK. m.p.barnes@btinternet.com

    Source

    Expert opinion on pharmacotherapy 7:5 2006 Apr pg 607-15

    MeSH

    Analgesics
    Cannabidiol
    Cannabinoids
    Dronabinol
    Drug Administration Schedule
    Drug Combinations
    Drug Therapy, Combination
    Humans
    Multiple Sclerosis
    Muscle Spasticity
    Pain
    Phytotherapy
    Plant Extracts
    Randomized Controlled Trials as Topic
    Self Administration
    Sleep Wake Disorders

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    16553576

    Citation

    Barnes, Michael Philip. "Sativex: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain." Expert Opinion On Pharmacotherapy, vol. 7, no. 5, 2006, pp. 607-15.
    Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006;7(5):607-15.
    Barnes, M. P. (2006). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion On Pharmacotherapy, 7(5), pp. 607-15.
    Barnes MP. Sativex: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain. Expert Opin Pharmacother. 2006;7(5):607-15. PubMed PMID: 16553576.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. A1 - Barnes,Michael Philip, PY - 2006/3/24/pubmed PY - 2006/8/26/medline PY - 2006/3/24/entrez SP - 607 EP - 15 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 7 IS - 5 N2 - Sativex is one of the first cannabis-based medicines to undergo conventional clinical development and to be approved as a prescription medicine. It is an oromucosal spray that allows flexible, individualised dosing. Patients self titrate their overall dose and pattern of dosing according to their response to and tolerance of the medicine. This usually results in the administration of approximately 8-12 sprays/day. Each spray delivers tetrahydrocannabinol 2.7 mg and cannabidiol 2.5 mg, giving an approximate average dose of tetrahydrocannabinol 22-32 mg/day and cannabidiol 20-30 mg/day. Development has concentrated on the treatment of symptoms of multiple sclerosis, notably spasticity and neuropathic pain, as well as the treatment of neuropathic pain of other aetiologies. Positive results in placebo-controlled trials of the use of Sativex as an add-on therapy in these indications demonstrate that Sativex is efficacious and well tolerated in the treatment of these symptoms. Sativex has been approved for use in neuropathic pain due to multiple sclerosis in Canada. If ongoing studies replicate the results already observed, further approvals for the treatment of spasticity in multiple sclerosis and for neuropathic pain are likely. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/16553576/Sativex:_clinical_efficacy_and_tolerability_in_the_treatment_of_symptoms_of_multiple_sclerosis_and_neuropathic_pain_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.7.5.607 DB - PRIME DP - Unbound Medicine ER -